EyeGate, Valeant Pharmaceuticals Sign Agreement Over Combination Product

EyeGate Pharmaceuticals has entered into a licensing agreement with Valeant Pharmaceuticals to market its EyeGate II delivery system and EGP-437 combination product for anterior uveitis, a type of eye inflammation.

The deal stipulates that EyeGate will receive an upfront cash payment, development-based and sales milestone payments, royalties and an approval-based payment upon receipt of FDA 510(k) marketing clearance, the Waltham, Mass., company said Friday.

The combination product contains an active corticosteroid, administered into the ocular tissues through the drug delivery system, designed to relive inflammation. It is being evaluated in clinical trials. — Jason Scott